GLPG2222

CFTR corrector

Phase of research

Phase Two Clinical Trial

How it helps

Restore CFTR Function

General information

GLPG2222 is an experimental substance used in studies and not yet available as a human pharmaceutical. In relation to cystic fibrosis, our AIM tool found the data that GLPG2222 can help correct the F508del-CFTR channel function.

GLPG2222 on PubChem
GLPG2222 on DrugBank

Synonyms

Galicaftor

Marketed as

N/A

Dietary sources

N/A

Structure not available

C28H21F4NO7

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
F508del/F508del
1 4.29
Link Tested on Impact factor Notes
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. humans 4.29

Does not treat

Mutation Number of sources Average impact factor